Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.

nmCRPC patients and caregivers preferred treatments with lower AE burdens and were willing to forego OS to reduce the risk and severity of AEs. Our results highlight the importance of carefully balancing risks and benefits when selecting treatments in this relatively asymptomatic population.